Novel strategy for treatment of pancreatic cancer by using EUS-FNAB samples

• Project/Area Number: 25461033
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Mie University
• Principal Investigator: Isaji Shuji 三重大学, 医学系研究科, 教授 (70176121)
• Co-Investigator(Kenkyū-buntansha): 水野 修吾 三重大学, 医学部附属病院, 講師 (70335131) ; 山田 玲子 (高山玲子 / 高山 玲子 / 山田 玲子(高山玲子)) 三重大学, 医学部, 助教 (80571629)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 膵癌 / EUS-FNAB / hENT1 / FNA

Outline of Final Research Achievements

By using Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy (EUS-FNAB) samples, we planed to establish personalized treatment for advanced pancreatic cancer. First we evaluated the relationship between Human equilibrative nucleoside transporter (hENT1) expressions assessed by immunohistochemical staining and clinical outcomes. We could discriminate whether the patients had a sensitivity of chemotherapy (gemcitabine) or not. In addition, we investigated immunohistochemical staining of dihydropyrimidine dehydrogenase (DPD: enzyme involved in the degradation of tegafur), and we revealed that DPD was useful of chemo sensitivity for TS-1.

Research Products

• [Journal Article] Human equilibrative nucleoside transporter 1 expression in endoscopic ultrasonography-guided fine-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemoradiotherapy (2016)
  • Author(s): Yamada R, Mizuno S, Uchida K, Yoneda M, Kanayama K, Inoue H, Murata Y, Kuriyama N, Kishiwada M, Usui M, Ii N, Tsuboi J, Tano S, Hamada Y, Tanaka K, Horiki N, Ogura T, Takei Y, Katayama N, Shiraishi T, Isaji S
  • Journal Title: Pancreas Volume: 45 Issue: 5 Pages: 761-771
  • DOI: 10.1097/mpa.0000000000000597
  • Peer Reviewed / Open Access
• [Journal Article] Gemcitabine-Based Chemoradiotherapy Followed by Surgery for Borderline Resectable and Locally Unresectable Pancreatic Ductal Adenocarcinoma: Significance of the CA19-9 Reduction Rate and Intratumoral Human Equilibrative Nucleoside Transporter 1 Expression. (2014)
  • Author(s): Kobayashi M, Mizuno S, Murata Y, Kishiwada M, Usui M, Sakurai H, Tabata M, Ii N, Yamakado K, Inoue H, Shiraishi T, Yamada T, Isaji S.
  • Journal Title: Pancreas Volume: 43 Issue: 3 Pages: 350-360
  • DOI: 10.1097/mpa.0000000000000059
  • Peer Reviewed
• [Presentation] 局所進行膵癌のEUS-FNAB検体中hENT1発現はGEM-CRTの治療効果と予後を予測する (2014)
  • Author(s): 山田、玲子、水野 修吾、伊佐地 秀司
  • Organizer: 第45回日本膵臓学会大会
  • Place of Presentation: 北九州国際会議場
  • Year and Date: 2014-07-11 – 2014-07-12